Abstract
AbstractPost‐mortem pathology data from nonclinical laboratory studies contain critical information for characterizing a new drug's safety and are pivotal for gaining an appreciation of potential hazards to humans. An understanding of the historical regulatory and scientific perspective on the nature of pathology data is valuable for assuring appropriate and useful audits of pathology material within nonclinical studies. This discussion reviews the specialty of pathology, the process of medical diagnosis, the definitions of ‘raw data’ as they pertain to histopathology data, and the rationale behind the consensus decisions made by industry and the Food and Drug Administration (FDA) in interpreting good laboratory practice (GLP) regulations for this type of data. Copyright © 2004 John Wiley & Sons, Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.